Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis

Heparin-lidocaine intravesical injection therapy for refractory interstitial cystitis - Heparin-lidocaine intravesical injection therapy for interstitial cystitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027918

Enrollment

Registered

2017-06-25

Start date

2016-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

interstitial cystitis

Interventions

heparin-lidocaine intravesical therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recurrence of interstitial cystitis was observed in the cystoscopy

Exclusion criteria

Exclusion criteria: 1. Patients with active urinary tract infection, urinary tract hemorrhage, urinary tract malignancy 2. Patients with systolic blood pressure of 200 mmHg or more or less than 89 mmHg and diastolic blood pressure of 80 mmHg or more 3. Patients with serious liver and kidney dysfunction 4. Patients with drug hypersensitivity such as allergies 5. Pregnant women and patients who may be pregnant or breast-feeding patients 6. Patients who participated in other clinical studies within 4 months 7. Patients whose research managers judged inappropriate as research subjects

Design outcomes

Primary

Measure	Time frame
urinary frequency	—

Countries

Japan

Contacts

Public ContactTomohiro Matsuo

Nagasaki University Hospital Department of Urology and Renal transplantation

tomo1228@nagasaki-u.ac.jp095-819-7340

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026